DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/pc2km6/masitinib) has announced the addition of the "Masitinib (Rheumatoid Arthritis) - Forecast and Market Analysis to 2023" report to their offering.
Rheumatoid arthritis (RA) is a chronic autoimmune disease which causes inflammation and deformity of the joints . It affects over seven million individuals in the 10MM covered in this report (US, France, Germany, Italy, Spain, UK, Japan, Australia, China, and India) and the prevalence is expected to grow to just over 8.5 million individuals by 2023.
The anti-TNFs have been effective in treating the signs and symptoms of RA and inhibiting progression to erosive bone disease. However, the landscape is quickly changing with the introduction of biosimilars, novel biologics, and a class of oral therapies known as JAK inhibitors, all of which will change the market dynamics between 2013 and 2023. With the anti-TNFs as extremely effective therapies for RA, the market is extremely competitive for new entrants and will undergo further pressure as biosimilars are approved and launch.
Masitinib is being developed in several indications, and is in Phase II or III of development for indications within cancer, central nervous system (CNS), and other inflammatory diseases. Masitinib is also currently in use in veterinary medicine for canine cancer, where it is known as Masivet or Kinavet (AB Science, 2014).
Key Topics Covered:
1 Tables & Figures
3 Disease Overview
4 Disease Management
5 Competitive Assessment
6 Unmet Need and Opportunity
7 Pipeline Assessment
For more information visit http://www.researchandmarkets.com/research/pc2km6/masitinib